-
Je něco špatně v tomto záznamu ?
Heart failure-related quality-of-life impairment after myocardial infarction
P. Wohlfahrt, D. Jenča, J. Stehlik, V. Melenovský, J. Mrázková, V. Staněk, J. Kettner, M. Šramko, M. Želízko, V. Adámková, J. Piťha, J. Kautzner
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
- MeSH
- anemie * MeSH
- hospitalizace MeSH
- infarkt myokardu * komplikace epidemiologie terapie MeSH
- kvalita života MeSH
- lidé MeSH
- srdeční selhání * epidemiologie terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
AIMS: Recent advances in therapy led to a significant decrease in mortality and morbidity after myocardial infarction (MI). However, little is known about quality of life (QoL) after MI. We examined heart failure (HF)-related quality-of-life (QoL) impairment, its trajectories, and determinants after MI. METHODS: Data from a single-center prospectively designed registry of consecutive patients hospitalized for MI at a large tertiary cardiology center were utilized. At 1 month and 1 year after hospital discharge, patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ). RESULTS: In total, 850 patients (aged 65 ± 12 years, 27% female) hospitalized between June 2017 and October 2020 completed KCCQ at 1 month after discharge. Of these, 38.7% showed HF-related QoL impairment (KCCQ ≤ 75). In addition to characteristics of MI (MI size, diuretics need, heart rate), comorbidities as renal dysfunction and anemia were associated with QoL impairment. Of the 673 eligible, 500 patients (74.3%) completed KCCQ at 1 year after MI. On average, QoL improved by 5.9 ± 16.8 points during the first year after MI (p < 0.001); but, in 18% of patients QoL worsened. Diabetes control and hemoglobin level at the time of hospitalization were associated with QoL worsening. CONCLUSION: Two out of 5 patients after MI present with HF-related QoL impairment. In addition to guideline-directed MI management, careful attention to key non-cardiac comorbidities as chronic kidney disease, anemia and diabetes may lead to further augmentation of the benefit of modern therapies in terms of QoL.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004845
- 003
- CZ-PrNML
- 005
- 20230425171744.0
- 007
- ta
- 008
- 230418s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00392-022-02008-z $2 doi
- 035 __
- $a (PubMed)35304902
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Wohlfahrt, Peter $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. wohlfp@gmail.com $u Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital, Videnska 800, 140 59, Prague, Czech Republic. wohlfp@gmail.com $1 https://orcid.org/000000032390526X
- 245 10
- $a Heart failure-related quality-of-life impairment after myocardial infarction / $c P. Wohlfahrt, D. Jenča, J. Stehlik, V. Melenovský, J. Mrázková, V. Staněk, J. Kettner, M. Šramko, M. Želízko, V. Adámková, J. Piťha, J. Kautzner
- 520 9_
- $a AIMS: Recent advances in therapy led to a significant decrease in mortality and morbidity after myocardial infarction (MI). However, little is known about quality of life (QoL) after MI. We examined heart failure (HF)-related quality-of-life (QoL) impairment, its trajectories, and determinants after MI. METHODS: Data from a single-center prospectively designed registry of consecutive patients hospitalized for MI at a large tertiary cardiology center were utilized. At 1 month and 1 year after hospital discharge, patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ). RESULTS: In total, 850 patients (aged 65 ± 12 years, 27% female) hospitalized between June 2017 and October 2020 completed KCCQ at 1 month after discharge. Of these, 38.7% showed HF-related QoL impairment (KCCQ ≤ 75). In addition to characteristics of MI (MI size, diuretics need, heart rate), comorbidities as renal dysfunction and anemia were associated with QoL impairment. Of the 673 eligible, 500 patients (74.3%) completed KCCQ at 1 year after MI. On average, QoL improved by 5.9 ± 16.8 points during the first year after MI (p < 0.001); but, in 18% of patients QoL worsened. Diabetes control and hemoglobin level at the time of hospitalization were associated with QoL worsening. CONCLUSION: Two out of 5 patients after MI present with HF-related QoL impairment. In addition to guideline-directed MI management, careful attention to key non-cardiac comorbidities as chronic kidney disease, anemia and diabetes may lead to further augmentation of the benefit of modern therapies in terms of QoL.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a kvalita života $7 D011788
- 650 12
- $a srdeční selhání $x epidemiologie $x terapie $7 D006333
- 650 _2
- $a hospitalizace $7 D006760
- 650 12
- $a infarkt myokardu $x komplikace $x epidemiologie $x terapie $7 D009203
- 650 12
- $a anemie $7 D000740
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jenča, Dominik $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Stehlik, Josef $u University of Utah School of Medicine, Salt Lake City, UT, USA
- 700 1_
- $a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Mrázková, Jolana $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Staněk, Vladimír $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Kettner, Jiří $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Šramko, Marek $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Želízko, Michael $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Adámková, Věra $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Piťha, Jan $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Kautzner, Josef $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 773 0_
- $w MED00155366 $t Clinical research in cardiology : official journal of the German Cardiac Society $x 1861-0692 $g Roč. 112, č. 1 (2023), s. 39-48
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35304902 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425171741 $b ABA008
- 999 __
- $a ok $b bmc $g 1925126 $s 1191054
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 112 $c 1 $d 39-48 $e 20220318 $i 1861-0692 $m Clinical research in cardiology $n Clin Res Cardiol $x MED00155366
- LZP __
- $a Pubmed-20230418